Skip to content
All resources

GLP-1 and metabolic

Survodutide: What the SYNCHRONIZE and MASH Trials Found

AM

By

· 10 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 8 sections
  1. What is survodutide?
  2. What did the early trials show?
  3. What did the SYNCHRONIZE phase 3 trials find?
  4. What did the liver trials find?
  5. What about heart rate and cardiovascular safety?
  6. What trials are still running?
  7. Is survodutide approved?
  8. Frequently asked questions

Survodutide (BI 456906) is Boehringer Ingelheim's investigational dual agonist of the GLP-1 and glucagon receptors. In the phase 3 SYNCHRONIZE-1 trial, adults with obesity and no diabetes had mean weight change of −12.2% to −13.0% at 76 weeks, against −5.4% on placebo. In SYNCHRONIZE-2, adults with obesity and type 2 diabetes had −8.2% to −9.8% against −3.9%. A phase 2 trial in MASH with fibrosis met its liver-histology endpoint. Survodutide is approved nowhere.

Liver cells with small lipid droplets, in the style of a micrograph
Illustration in the style of a micrograph, not experimental data: liver fat, one of the endpoints these trials measured.

What is survodutide?

Survodutide is a single synthetic peptide that activates two receptors: the GLP-1 receptor, the target of semaglutide, and the glucagon receptor. It carries a C18 fatty acid that extends its half-life. Boehringer Ingelheim's discovery paper describes it as a potent dual agonist and reports that, in mice, it reduced body weight more than semaglutide at maximally effective doses, through both lower food intake and higher energy expenditure. Engagement of the glucagon receptor was shown through liver gene expression and circulating amino acids, and of the GLP-1 receptor through glucose tolerance, food intake and gastric emptying tests. Those are rodent findings.

The idea behind adding glucagon is covered in glucagon receptor agonists explained. The short version is that glucagon acts directly on the liver and may raise energy expenditure, while GLP-1 agonism lowers food intake and keeps glucose in check. How the three incretin-family receptors differ is set out in the receptor guide.

Survodutide's closest relatives are mazdutide, another GLP-1/glucagon dual agonist that is approved in China, and pemvidutide. Retatrutide adds the GIP receptor to the same pair.

What did the early trials show?

Phase 1. Two phase 1 studies tested single and multiple rising doses in healthy volunteers and people with overweight or obesity. In the multiple-dose study, the largest placebo-corrected weight change was −13.8% at week 16. Plasma amino acids and glucagon fell, which the authors read as evidence the drug was engaging both receptors. One detail is worth noting: in the faster-escalation part of that study, 7.5% of participants stopped because of a cardiac or vascular adverse event.

Phase 2 in type 2 diabetes. Blüher and colleagues randomised 413 people with type 2 diabetes on metformin to survodutide at several dose levels, placebo or open-label semaglutide for 16 weeks. HbA1c fell by up to 1.71 percentage points. At its lower dose levels survodutide lowered HbA1c about as much as semaglutide did, and at the higher levels it reduced weight more: up to −8.7% against −5.3% with semaglutide. Adverse events, mainly gastrointestinal, were reported by 77.8% on survodutide against 52.5% on placebo and 52.0% on semaglutide.

Phase 2 in obesity. le Roux and colleagues enrolled 387 adults without diabetes in 43 centres and 12 countries for 46 weeks. Mean weight change ranged from −6.2% to −14.9% across the doses studied, against −2.8% with placebo. Only 60.4% of participants completed the 46 weeks, and gastrointestinal adverse events affected 75% of those on survodutide against 42% on placebo.

What did the SYNCHRONIZE phase 3 trials find?

The obesity programme is called SYNCHRONIZE. Both main trials ran for 76 weeks, used two dose levels against placebo, and had two primary endpoints: percent change in body weight, and the share of participants losing at least 5%.

SYNCHRONIZE-1 randomised 725 adults with obesity, or overweight with a complication, and no diabetes. Mean baseline BMI was 37.9. Using the treatment-regimen estimand, which counts everyone randomised and includes the effect of stopping early, mean weight change was −12.2% and −13.0% in the two survodutide groups against −5.4% on placebo. At least 5% weight reduction was reached by 72.6%, 71.9% and 46.3% respectively. Gastrointestinal symptoms, typically mild to moderate, occurred in 80.9% and 89.7% of survodutide recipients against 47.9% on placebo.

SYNCHRONIZE-2 randomised 752 adults with type 2 diabetes and a BMI of 27 or more. Weight change was −8.2% and −9.8% against −3.9% on placebo. HbA1c, from a baseline of 7.4%, fell by 0.9 and 0.8 percentage points against 0.2 on placebo. Gastrointestinal events affected 72.8% and 77.7% against 38.6%.

Two things stand out. First, the phase 3 figures are smaller than the upper end of the phase 2 range. Partly that reflects a different estimand and a larger, more varied population, and partly it is the usual shrinkage between a dose-finding trial and a confirmatory one. Second, the placebo group in SYNCHRONIZE-1 lost 5.4%, more than in many obesity trials, which narrows the gap. Comparing these figures with other drugs' trials runs into the problems described in the study design guide.

What did the liver trials find?

Liver disease is the second half of the survodutide programme, and it is where the glucagon hypothesis is most directly tested.

Phase 2 in MASH. Sanyal and colleagues randomised adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and fibrosis stage F1 to F3 for 48 weeks. Of 293 participants who received treatment, improvement in MASH with no worsening of fibrosis occurred in 43% to 62% across the doses studied, against 14% on placebo. Fibrosis improved by at least one stage in 34% to 36% against 22%, a secondary endpoint. Nausea (66% against 23%), diarrhoea (49% against 23%) and vomiting (41% against 4%) were more common on survodutide; serious adverse events occurred in 8% against 7%.

SYNCHRONIZE-MASLD, a phase 3 trial, enrolled 216 adults with obesity and at-risk fatty liver disease in the United States and Spain for 48 weeks. Its co-primary endpoints were a relative reduction of at least 30% in liver fat measured by MRI and percent change in body weight. Using the efficacy estimand, 84.2% on survodutide reached the liver-fat threshold against 24.3% on placebo; with the treatment-regimen estimand it was 68.5% against 28.6%. Weight change was −12.2% against −1.0% (efficacy estimand), or −8.7% against −1.4% (treatment-regimen). The authors list the short duration and limited geographic reach as limitations.

Liver fat by MRI is a surrogate endpoint. Whether it predicts fewer cases of cirrhosis or liver failure is what the larger outcome trials are for; the difference is explained in surrogate endpoints explained.

TrialPopulationDurationPrimary result
Phase 2 obesityNo diabetes; 387 enrolled46 weeksWeight −6.2% to −14.9% vs −2.8%
Phase 2 MASHBiopsy-confirmed MASH, F1–F3; 293 treated48 weeksMASH improvement 43–62% vs 14%
SYNCHRONIZE-1Obesity, no diabetes; 72576 weeksWeight −12.2% and −13.0% vs −5.4%
SYNCHRONIZE-2Obesity with type 2 diabetes; 75276 weeksWeight −8.2% and −9.8% vs −3.9%
SYNCHRONIZE-MASLDObesity with at-risk MASLD; 21648 weeks≥30% liver-fat reduction 84.2% vs 24.3%

What about heart rate and cardiovascular safety?

Glucagon at high exogenous doses raises heart rate and blood pressure, so cardiovascular safety is the obvious question for any glucagon co-agonist. A 2026 review by Kushner and Michos concluded that clinical studies of GLP-1/glucagon dual agonists, survodutide and mazdutide among them, have generally found heart-rate increases similar to those with GLP-1 agonists alone. The same review notes that at least one other dual agonist was discontinued partly because of large heart-rate increases and QT prolongation, and that these differences may reflect how strongly each compound activates each receptor. The authors name a thorough QT study of survodutide and the cardiovascular outcomes trial as the places where survodutide's own answer will come from.

That outcomes trial, SYNCHRONIZE-CVOT (NCT06077864), enrolled adults with overweight or obesity and established cardiovascular or kidney disease or multiple risk factors. Its primary endpoint is time to a first five-point major adverse cardiovascular event. The registry lists it as completed with 5,531 participants; no results had appeared on PubMed by late October 2026.

What trials are still running?

ClinicalTrials.gov lists a broad phase 3 programme beyond the trials above, all sponsored by Boehringer Ingelheim:

  • LIVERAGE (NCT06632444), in MASH with moderate or advanced fibrosis, recruiting about 1,800 participants.
  • LIVERAGE-Cirrhosis (NCT06632457), in MASH with cirrhosis. A separate phase 2 study in cirrhosis has been published.
  • SYNCHRONIZE-JP (NCT06176365) and a Chinese obesity trial (NCT06214741), both listed as completed.
  • A glycaemic-control trial in type 2 diabetes (NCT07754461), and trials in women around menopause (NCT07850050) and in heart structure in fatty liver disease (NCT07850063), recruiting or not yet recruiting.

What these trials measure and when they finish can change; the guide to reading a ClinicalTrials.gov record explains what each field does and does not tell you.

Is survodutide approved?

No regulatory approval for survodutide could be confirmed for this article, in Canada or elsewhere. The SYNCHRONIZE-2 paper, published in October 2026, still describes it as investigational, and a 2026 review states that it is not approved for routine clinical use. Its cardiovascular outcome results, long-term safety and effects after stopping have not been published. Health Canada's Drug Product Database is where any Canadian authorisation would appear.

Survodutide sits in a crowded field. The 2026 incretin pipeline overview sets it beside the approved drugs and the other late-stage candidates, including amycretin and MariTide.

NovaEvum does not carry survodutide. Nothing here is medical, dosing, or therapeutic guidance.

Frequently asked questions

How much weight did people lose on survodutide in phase 3? In SYNCHRONIZE-1, adults with obesity and no diabetes had mean weight change of −12.2% and −13.0% at 76 weeks on the two dose levels, against −5.4% on placebo, counting everyone randomised. In SYNCHRONIZE-2, in people with type 2 diabetes, the figures were −8.2% and −9.8% against −3.9%.

Why were the phase 3 results smaller than phase 2? The phase 2 trial reported up to −14.9% at 46 weeks in a smaller dose-finding population, analysed differently. Phase 3 used a treatment-regimen estimand that counts early discontinuation, enrolled more varied participants, and had a placebo group that lost 5.4%. Shrinkage between phase 2 and phase 3 is common.

What does survodutide do to the liver in trials? In a phase 2 trial in biopsy-confirmed MASH, improvement without fibrosis worsening occurred in 43% to 62% of participants on survodutide against 14% on placebo. In SYNCHRONIZE-MASLD, 84.2% reached a 30% liver-fat reduction by MRI against 24.3% on placebo. Larger fibrosis and cirrhosis trials are still running.

What are survodutide's side effects? Mainly gastrointestinal. In SYNCHRONIZE-1, nausea, vomiting, diarrhoea and related symptoms occurred in 80.9% to 89.7% of survodutide recipients against 47.9% on placebo, typically mild to moderate. Heart-rate effects in dual-agonist trials have generally resembled those of GLP-1 agonists, but survodutide's cardiovascular outcome results are unpublished.

Is survodutide the same as mazdutide? No. Both are dual GLP-1/glucagon receptor agonists, but they are different molecules from different companies, with different potency at each receptor. Survodutide is developed by Boehringer Ingelheim and is approved nowhere. Mazdutide, from Innovent and Eli Lilly, received approval in China in 2025.

Selected Research References

  1. Zimmermann T, Thomas L, Baader-Pagler T, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Molecular Metabolism. 2022;66:101633. pubmed.ncbi.nlm.nih.gov/36356832
  2. Jungnik A, Arrubla Martinez J, Plum-Mörschel L, et al. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, Obesity and Metabolism. 2023;25:1011-1023. pubmed.ncbi.nlm.nih.gov/36527386
  3. Blüher M, Rosenstock J, Hoefler J, et al. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2024;67:470-482. pubmed.ncbi.nlm.nih.gov/38095657
  4. le Roux CW, Steen O, Lucas KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology. 2024;12:162-173. pubmed.ncbi.nlm.nih.gov/38330987
  5. Sanyal AJ, Bedossa P, Fraessdorf M, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. New England Journal of Medicine. 2024;391:311-319. pubmed.ncbi.nlm.nih.gov/38847460
  6. le Roux CW, Wharton S, Startseva E, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. New England Journal of Medicine. 2026;395:776-787. pubmed.ncbi.nlm.nih.gov/42253238
  7. Wharton S, le Roux CW, Startseva E, et al. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. New England Journal of Medicine. 2026. pubmed.ncbi.nlm.nih.gov/42820639
  8. Kaplan LM, Startseva E, le Roux CW, et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nature Medicine. 2026;32:2948-2958. pubmed.ncbi.nlm.nih.gov/42252333
  9. Kushner PR, Michos ED. Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus. Journal of the American Heart Association. 2026;15:e049727. pubmed.ncbi.nlm.nih.gov/42535526

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.